Roche $ROG (-0,63 %) has recently faced challenges in its pursuit of developing new obesity treatments, particularly with its GLP-1 drugs. Initial trial results had raised hopes for a potential blockbuster, showcasing significant weight loss among participants. However, recent disclosures about side effects, particularly high rates of vomiting, have led to a drop in Roche's stock prices, reflecting investor concerns.During recent trials, it was reported that about 75% of patients receiving the highest dose of Roche's CT-388 injection experienced vomiting. This revelation caused Roche's shares to decline by 4% on Monday and an additional 5% later in the week after similar findings were released for its oral weight-loss pill. Analysts noted that Roche's optimistic presentation of early trial data may have set unrealistic expectations, leading to a backlash when the side effects became apparent.The GLP-1 drug market is highly competitive, dominated by established players like Novo Nordisk and Eli Lilly. These companies have successfully launched treatments that not only aid in weight loss but also manage diabetes, with the market projected to grow significantly in the coming years. Analysts estimate that the GLP-1 market could reach $130 billion annually by 2030, driven by increasing demand for effective obesity and diabetes treatments.Despite the setbacks, Roche remains committed to its drug development, with company officials stating that the side effects observed are consistent with other GLP-1 treatments. They plan to adjust dosing strategies in future trials to improve tolerability. Other companies are also exploring new formulations and combinations of hormones to mitigate side effects and enhance efficacy, indicating that the race for effective obesity treatments is far from over.
Roche HoldingsCH0012032048ROGROG
$ROG (-0,63 %) / $RHHBY (-0,84 %) - Demands $LLY (-0,28 %) and $NOVO B (+1,53 %) challenging?
The Swiss drug manufacturer Roche $ROG (-0,63 %) is planning to accelerate the development of its obesity drugs in order to beat rivals such as Eli Lilly $LLY (-0,28 %) and Novo Nordisk $NOVO B (+1,53 %) in the booming market, the Financial Times reported on Monday.
Roche is among a growing number of potential rivals to Novo and Eli Lilly, whose weight-loss injections are in feverish demand, with experts raising their sales forecasts for such treatments to as much as $150 billion by the early 2030s.
Roche CEO Thomas Schinecker told the newspaper that the first obesity drugs "will come to market much faster than people expect"possibly by 2028.
Earlier this month, the company said its second drug candidate, an experimental once-daily pill it acquired through the purchase (link) of Carmot Therapeutics, had shown positive results in an early-stage trial. Schinecker told the FT that Roche could have "about seven" drugs from the Carmot acquisition, several of which are in earlier stages of development.
Roche did not immediately respond to Reuters' request for comment.
Happy Monday!
GG
Source: Reuters
$ROG (-0,63 %) Roche is confident of higher profits for the year as a whole.
The pharmaceutical company Roche can look back on a solid first half-year.
Business is going so well that the Group is now raising its profit outlook for the year as a whole.
As $ROG (-0,63 %) announced on Thursday, Group sales were on a par with the previous year at 29.8 billion francs. At constant exchange rates, however, it rose by 5 percent. And excluding the Covid-19 sales, sales would have increased by as much as 8 percent. The second quarter in particular showed accelerated growth momentum with an increase of 9% at constant exchange rates.
The important pharma division achieved sales of 22.6 billion Swiss francs in the first half of the year, an increase of 1 percent. Business was driven by sustained high demand for newer drugs. The eye medicine Vabysmo in particular once again proved to be the most important growth driver.
Roche generated sales of 7.2 billion (-1%) with its diagnostics. This smaller division in particular had seen a real boom in coronavirus times due to the tests.
The bottom line was a net profit according to IFRS of 6.7 billion, down 11% on the prior-year period. The decline was due in particular to the impairment of intangible assets for products and technologies in research and development as a result of strategic decisions.
Core operating profit, on the other hand, which analysts primarily look at, rose by 4 percent to 11.3 billion. Roche attributes the increase to the sales trend and its cost management.
Better than expected
With the reported figures, Roche has slightly exceeded analysts' average estimates.
Based on the half-year results, the pharmaceutical company is raising its previous profit outlook for the year as a whole. Core earnings per share are now expected to increase in the high single-digit percentage range (previously: mid single-digit percentage range). Management continues to expect a mid-single-digit percentage increase in sales at constant exchange rates. As always, the Group aims to increase the dividend in Swiss francs
In view of the expected impact of the discontinuation of Covid sales, Roche continues to expect a negative impact on sales of 1.1 billion Swiss francs. By contrast, the erosion of sales due to copycat products is likely to have a somewhat less pronounced impact. Roche has adjusted its forecast here to -1.4 billion. Most recently, the Group was still forecasting 1.6 billion.
Balance sheet data will be published today at 2 pm according to TR.
(Switzerland) - The most important dates for this trading week
This week is the best of the year for real number crunchers: More than forty listed companies will present their half-year report. These include small companies such as the Walliser Kantonalbank (WKBN), but also big names on the Swiss market such as $ROG (-0,63 %) and $NESNE / $NESN (-0,84 %) . Naturally, observers will be keeping a close eye on the outlook for the second half of the year.
On Monday, only the climate specialist Belimo $B9H will report on the first half of the year.
Seven companies have announced their reports for Tuesday. These are the logistics company Kuehne + Nagel $KNIN (-1,04 %)
, the chocolate manufacturer Lindt & Sprüngli
$LISN (-0,44 %) and the fragrance producer Givaudan $GIVN (-0,05 %)
, also reporting Logitech $LOGN (+0,84 %), Dätwyler $DAE (+1,93 %)
, Temenos $TEMN (-0,59 %) and the Valais Cantonal Bank ($WKBN). At Lindt & Sprüngli $LISN (-0,44 %) will be watching for comments on the high cocoa prices. At Kühne + Nagel $KNIN (-1,04 %) the renewed increase in the complexity of sea transportation due to the threat to shipping in the Red Sea could have an initial positive effect.
On Wednesday, nine companies will give an insight into their finances. For example, the goods inspector SGS
$SGSN (-1,73 %) and also Bobst ($BOBNN) , So $ALSN (+0,53 %)
Cembra Money Bank $CMBN (-0,57 %)
, Cicor $CICN (+1,62 %)
Cosmo Pharmaceuticals $COPN (+0,91 %)
EFG International $EFGN (+0,99 %)
and Medacta $MOVE (+0,99 %)
. At SGS $SGSN (-1,73 %) it is to be expected that, as in previous quarters, decent sales growth will be offset by negative exchange rate effects.
Thursday is the highlight of the interim reporting season: a total of sixteen company reports are on the agenda. Among them are Nestlé $NESN (-0,84 %)
, Roche $ROG (-0,63 %)
, Lonza
$LONN (+1,36 %) and Julius Baer $BAER (+1,25 %)
, but also Bachem $BANB, Bucher $BUCN (+2,76 %)
, Galderma $GALD
, Autoneum $AUTN (+1,55 %)
, Bellevue $BBN (+0,14 %)
, Calida $CALN (-0,59 %)
, Idorsia $IDIA (-0,76 %)
, Leonteq $LEON (+0,63 %)
, the Graubündner Kantonalbank $GRKP (-0,28 %)
, Meier Tobler $MTG (+1,82 %)
, StarragTornos $STGN and Valiant $VATN (-0,38 %)
. At Nestlé $NESN (-0,84 %) the question is whether a return to positive growth rates can be achieved.
Many listed companies have once again announced their half-year figures for Friday. They include Holcim $HOLN (+2,15 %)
Sulzer $SUN (+2,76 %)
, Vontobel $VONN (+0,6 %)
, Forbo $FORN (+2,8 %)
, APG $APGN (-0,24 %)
, Zehnder $ZEHN (+0,44 %)
, Orell Füssli $OFN (-0,37 %)
, Lem $LEHN (+4,46 %)
, AMS Osram $AMS (+2,83 %) and BB Biotech $BION (+1,21 %) and the SIX as the operator of the Swiss stock exchange. The industrial group Sulzer $SUN (+2,76 %) should deliver a positive surprise after a strong performance that has been ongoing for some time.
Have a good week everyone!
GG
Roche
$ROG (-0,63 %) 🇨🇭hat in a phase 1 study with the weight loss tablet
CT-996 achieved positive results, with an average weight loss of 7.3 percent in four weeks.
CT-996 belongs to the class of GLP-1 weight loss drugs originally developed for the treatment of diabetes. diabetes treatment and reduce appetite.
These drugs also include the well-known weight loss injection Wegovy from Novo Nordisk
$NOVO B (+1,53 %) and the drug Zepbound from Eli Lilly
$LLY (-0,28 %).
One tablet form could significantly increase demand, which is why competitors are also working on such tablets.
